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Abstract
Spinal cord stimulators (SCS) are a well-recognised treatment modality in the management of a number of chronic
neuropathic pain conditions, particularly failed back syndrome and radiculopathies. The implantable pulse
generator (IPG) component of the SCS is designed and operates in a similar fashion to that of a cardiac pacemaker.
The IPG consists of an electrical generator, lithium battery, transmitter/receiver and a minicomputer. When
stimulated, it generates pulsed electrical signals which stimulate the dorsal columns of the spinal cord, thus
alleviating pain. Analogous to a cardiac pacemaker, it can be potentially damaged by ionising radiation from a
linear accelerator, in patients undergoing radiotherapy. Herein we report our clinical management of the first
reported case of a patient requiring adjuvant breast radiotherapy who had a SCS in situ. We also provide useful
practical recommendations on the management of this scenario within a radiation oncology department.
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Background
Radiotherapy (RT) is a major cancer treatment modality,
applied to approximately 60% of patients at some point
in their natural history for curative and palliative intent
[1]. However, RT can interfere with and potentially
damage implanted electronic devices such as cardiac
pacemakers or implanted cardioverter-defibrillators
(ICD) [2]. Given the increasing use of these devices for
a broad range of medical applications, recommendations
have been developed regarding the safe delivery of RT
with such devices in-situ [3,4]. Safety guidelines do not
yet exist however, for implanted electronic spinal cord
stimulators (SCS).
Spinal cord neuromodulation using implantable elec-
trodes placed over the dorsal columns in the epidural
space can be an effective strategy for the control of
severe, longstanding, neuropathic pain [5,6]. The SCS
system consists of 3 components: an electrode array
which is implanted in the epidural space overlying the
dorsal columns of the spinal cord; an implantable pulse
generator (IPG) which consists of an electrical
generator, battery, transmitter/receiver and a minicom-
puter, which is placed beneath the skin and controlled
transcutaneously by the patient; and insulating wiring
connecting the electrodes to the IPG. These devices are
an important treatment modality for chronic neuro-
pathic pain conditions refractory to conservative man-
agement, including complex regional pain syndrome,
radiculopathies, failed back syndrome, phantom limb
pain, and post-herpetic neuralgia. They are increasingly
applied to other conditions including intractable angina
and ischemic pain secondary to peripheral vascular dis-
ease, though long-term efficacy remains undetermined
[7].
Surgical techniques for SCS implantation are largely
similar regardless of indication and are typically per-
formed in two stages. One to four leads are placed in
the epidural space in the cervical, thoracic or lumbar
regions as appropriate, either percutaneously or via a
small laminotomy. The SCS can also be placed to cover
exiting nerve roots in the epidural space, in addition to
or instead of posterior placement over dorsal columns.
The leads are inserted under local anesthesia with seda-
tion, following which they are connected to an external
connector lead and controller that allows the patient to
manipulate the device once ambulating. The majority of
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patients are trialled as out-patients. Less commonly
patients can remain in hospital for 2-5 days after the
procedure during which time pain level and functional
capacity improvements are assessed. The system is
deemed suitable for insertion (stage 2) if there is ade-
quate pain relief (typically greater than 50% pain relief)
and lack or minimal side effects of stimulation. The IPG
is then implanted into a subcutaneous pocket and con-
nected to the leads. Typical IPG locations include the
gluteal and flank regions, with sub-clavicular and
abdominal wall placement performed less frequently [8].
The IPG closely resembles and operates similarly to a
cardiac pacemaker, generating pulsed electrical signals
which stimulate the dorsal columns. The amplitude
(intensity), frequency, and width of the stimulating elec-
trical signals can be adjusted for the desired effect. The
IPG contains a battery similar to that of a cardiac pace-
maker, typically a single lithium thionyl chloride cell or
lithium-iodine battery. The terminals of the battery cell
are connected to the input terminals of the voltage reg-
ulator, which provides power to the logic and control
section of the IPG. The logic and control section
includes a microprocessor and controls the programma-
ble functions of the device via a crystal oscillator
(Rutecki: United States Patent, Number 5330515, July
1994). When irradiated however, the IPG could be
potentially damaged by the ionizing radiation itself, or
by electromagnetic interference generated from the lin-
ear accelerator, in the same way that ionising radiation
can damage a cardiac pacemaker or ICD.
Herein, we present the first reported case of a patient
with a SCS in-situ, who required adjuvant RT for breast
cancer. We outline our management plan in ensuring
the safe delivery of radiation for this patient, and suggest
recommendations for the management of this uncom-
mon, but potentially serious clinical scenario.
Clinical Case
A 46 year old peri-menopausal woman, with no known
breast cancer risk factors, self-detected a left breast
mass. Digital mammography identified a 10 cm mass
occupying the left breast. Biopsy identified a grade 3
ductal carcinoma in-situ (DCIS). Fine needle aspiration
of a left axillary node identified invasive ductal carci-
noma (IDC). Metastatic work-up was negative for dis-
tant disease. Clinical stage was hence T3N1M0.
A left-sided mastectomy and axillary lymph node dis-
section was performed. Pathological analysis identified
multi-focal grade 3 IDC, the largest focus measuring 0.4
cm, on an 8.6 cm background of grade 3 DCIS, with
extensive lymphovascular space invasion. Two of four-
teen lymph nodes were positive for metastatic disease.
The closest surgical margin to invasive disease was 1
mm; 2 mm for the DCIS. Oestrogen and progesterone
receptors were negative, but HER-2/neu was positive.
Pathological stage was T1aN1aM0 (multi-focal).
Multidisciplinary tumor board discussion recom-
mended adjuvant loco-regional RT, in view of extensive
grade 3 DCIS, node positivity, and close surgical mar-
gins. Adjuvant systemic chemotherapy plus trastuzumab
was also recommended.
Prior to her cancer diagnosis, this patient had an 8-
year history of chronic back pain, following an acute
posterior L4-L5 disc herniation, requiring urgent lumbar
spine decompression. Her pain was further aggravated
following a motor vehicle accident. She underwent
spinal fusion for L5-S1 spondylolisthesis in 2005 (Figure
1). Her lack of relief of chronic leg pain eventually
resulted in the diagnosis of failed back surgery syn-
drome (FBSS). Given the severity of her neuropathic
radicular pain, the lack of adequate response to conser-
vative measures, and the interference of pain with her
daily life, she subsequently had a SCS inserted (Figure
1). She obtained a good response with decreased neuro-
pathic pain and increased mobility. The patient-con-
trolled device allows her to “dial” the stimulus to effect,
within a pre-arranged stimulus range. She can also turn
the device off, if necessary.
Following initial consultation with Radiation Oncol-
ogy, a thorough literature search was initiated regarding
the delivery of RT to patients with a SCS, which yielded
no reports. We sought advice from her consultant neu-
rosurgeon (MH), who specializes in SCS placement. The
device manufacturer Medtronic® was contacted and
device specifications obtained (Prime Advanced, Model:
37702, Serial number: NKL706993H). The verbal recom-
mendation from the manufacturer was to avoid direct
irradiation of the device. She consented for RT, follow-
ing a discussion highlighting the benefits and risks of
treatment, including the measures to be undertaken to
protect her SCS.
Radiotherapy Planning
The patient underwent a simulation-CT scan in a stan-
dard treatment position. Given our concern regarding
the effects of RT on the IPG in her right iliac fossa, the
entire device was imaged on the simulation-CT. By con-
touring the IPG, an estimation of the received dose by
the IPG during RT delivery was calculated, giving a dose
of 0.7 cGy per fraction. The device was 22 cm from the
inferio-medial radiation field edge. An IMRT technique
to encompass the left chest wall and supra-clavicular
fossa was used. Dose to organs at risk was minimized
according to internationally recognised dose constraints.
Radiotherapy Delivery
Treatment was delivered with 6 MV photons, adminis-
tering daily 200 cGy fractions to a total dose of 5000
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cGy over 5 weeks (Elekta Synergy). During RT delivery,
the patient turned off her SCS. Dosimetric readings
were obtained on three separate occasions during RT
using metal oxide-silicon semiconductor field effect
transistor (MOSFET) diodes. These were placed on the
skin surface in build-up material on the patient’s right
iliac fossa (opposite side of treatment field). Readings








Figure 1 An AP X-ray demonstrating position of the epidural spinal cord stimulation electrode, connector wires, and pulse generator
located in the right lower quadrant. The patient’s prior instrumentation in the lumbo-sacral area is also visualized.
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that the IPG had been originally placed in that location
(same side as treatment field) (Table 1). Treatment was
completed as planned. The maximum acute toxicity was
grade 2 radiation dermatitis.
Discussion and Recommendations
Apart from this case report, specific investigations
regarding the impact of RT on SCS systems have not
been performed to date, perhaps partly accounted for by
how infrequently this clinical scenario arises. However,
given that the range of indications for SCS continues to
expand, it is imperative that guidelines exist regarding
the safe delivery of RT to a patient with a SCS in situ.
As we have described above, the IPG component of the
SCS operates similarly to that of a cardiac pacemaker,
and therefore it is possible to extrapolate from the evi-
dence of cardiac devices to understand how RT can be
damaging to implanted electronic devices; hence deter-
mining what safety procedures should be followed.
The radiation effects on cardiac devices have been
widely studied, with safety recommendations provided
[4,9-12]. The potential damaging effects are two-fold: a)
interference caused by electromagnetic interference
(EMI) from the linear-accelerator; and b) effects result-
ing from direct radiation beams. Damage is dependent
on the total delivered dose, the type of radiation used,
and the device specifications. Damage can be caused
when the device is on or off, can be transient, or can
result in permanent re-arrangements of the atoms
within the semiconductor crystal [13].
Last et al described how ionizing radiation can affect
cardiac pacemaker function [14]. When directly irra-
diated, electron-hole pairs are created in the silicon and
silicon-dioxide semiconductor materials. Once the radia-
tion is off, the electron-hole pairs rapidly recombine,
and the electrons leave quickly by flowing to the metal
or semiconductor within the oxide. This can result in
either transient or permanent changes within the pace-
maker. The holes being relatively immobile remain in
the valence band, and are attracted by structural defects,
which can lead to an accumulation of trapped positive
charges, also deleterious to the pacemaker. The trapped
charges in the oxide can in turn produce an alteration
in the current-voltage characteristics of the device,
potentially causing aberrant electrical pathways.
Venselaar et al examined the effects of ionizing radia-
tion on pacemakers irradiated in a cobalt-60 beam, and
the influence of EMI by two linear-accelerators [15]. In
the cobalt-60 beam, two pacemakers demonstrated a
decrease in pulse repetition frequency when irradiated
to therapeutic dose levels, with two others demonstrat-
ing pacing failure at 97 Gy and 147 Gy, respectively.
When determining EMI sensitivity, an inhibition of one
pacemaker pulse occurred when one linear accelerator
was turned on and off.
The American Association of Physicists in Medicine
(AAPM) issued guidelines in 1994 for the safe irradia-
tion of patients with pacemakers [3]. In contrast to Ven-
selaar et al, this report stated that EMI effects were both
negligible and transient when modern contemporary lin-
ear-accelerators were used; hence EMI was not a cause
for concern. However, it acknowledged that the harmful
effects of the radiation itself remained.
Mouton et al irradiated 96 different pacemakers, with
different dose rates and fraction sizes [16]; 14.6%
demonstrated a clinically relevant failure under 5 Gy,
with a 6% failure rate even below 2 Gy. Hurkmans et al
investigated the newest generation of ICDs and cardiac
pacemakers [9,10]. Eleven modern, unused ICDs were
irradiated to 20 Gy in seven fractions. Subsequent irra-
diation was to a definite point of failure or to 120 Gy.
Whilst most withstood irradiation to ≥ 80Gy, some dis-
played serious malfunctions, including complete loss of
function in four devices at doses as low as 2.5 Gy. Inap-
propriate shock delivery occurred in four instances. No
EMI was recorded.
Given that no formal safety guidelines were available
to us in our management of this patient, we initially cal-
culated the expected dose to be received by the IPG at
the time of RT planning, giving an estimated total dose
of 18.4 cGy for all 25 fractions. In addition, diode read-
ings were taken on 2 separate occasions with 4 measure-
ments on each occasion. This approach, in addition to
the safety procedures recommended for cardiac pace-
makers, forms the basis of the practice guidelines we
have developed for the safe delivery of RT to patients
with a SCS in situ. It is important to recognise however,
that there are limitations to these guidelines. We have
no measurement of the maximum tolerated dose of the
device, and the 5 Gy limit is the extrapolation from the
use of cardiac pacemakers, where the consequences of
damage can be life-threatening. It is certainly possible
that a higher dose limit could be recommended for the
Table 1 Semiconductor diode surface measurements at
the pulse generator location (patient’s right side,
contralateral to radiation fields)
Diode Readings: Right Iliac Fossa Diode Readings: Left Iliac Fossa
Reading 1: 0.00 cGy Reading 1: 0.32 cGy ± 0.3 cGy †
Reading 2: 0.00 cGy Reading 2: 0.00 cGy
Reading 3: 1.11 cGy ± 0.32 cGy* Reading 3: 0.33 cGy ± 0.2 cGy
Readings were also performed on patient’s left side (ipsilateral to radiation
fields).
*Had the pulse generator received this dose at each fraction this would have
equated to a total dose of 27.7 cGy ± 8.1 cGy over a total radiation schedule
of 50 Gy in 25 fractions of 2 Gy each (= 0.5% of total dose).
† Had the pulse generator received this dose at each fraction, this would have
equated to a total dose of 8 cGy ± 7.5 cGy over a total radiation schedule of
50 Gy in 25 fractions of 2 Gy each (= 0.16% of total dose).
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SCS system; however in the absence of any dosimetric
data from our own institution or from the available lit-
erature supporting a higher dose limit, we would cur-
rently recommend a 5 Gy limit. It is also possible that
different SCS systems with varying device specifications
have different radiation tolerances, as is the case with
cardiac pacemakers and ICDs. It is also important to
state that if the IPG is within the radiation field, it
might be more feasible to actually remove it with or
without the connecting leads, but leaving the epidural
electrode in place. These can be reinserted later with
minimal morbidity. Accepting these limitations, we
would recommend adherence to the guidelines as out-
lined in Table 2. These guidelines provide general safety
recommendations, in addition to advocating a step-by-
step approach to the simulation, planning and delivery
of radiation to patients with a SCS in situ.
Conclusion
Whilst the consequences of RT on the IPG may not be
as serious as those on pacemakers or ICDs, and while
further dosimetric data regarding the radiation tolerance
of such SCS systems remain to be generated, in the
interim, both the planning and delivery of RT to those
with an implanted SCS should follow a methodical
approach to ensure its safe delivery. This will help to
avoid any unnecessary damage to the device, which
could result in significant pain and morbidity for the
patient, and the possible requirement to replace such a
device.
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